Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal

Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment. Market Domination hosts Julie Hyman and Josh Lipton take a closer look at the details of the deal. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.